Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Magnus Financial Group LLC

Magnus Financial Group LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 37.0% in the 1st quarter, HoldingsChannel.com reports. The fund owned 1,210 shares of the medical research company’s stock after buying an additional 327 shares during the quarter. Magnus Financial Group LLC’s holdings in Amgen were worth $377,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Centricity Wealth Management LLC acquired a new position in shares of Amgen in the fourth quarter worth $25,000. Pinney & Scofield Inc. acquired a new position in shares of Amgen in the fourth quarter worth $26,000. Ritter Daniher Financial Advisory LLC DE lifted its position in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock worth $33,000 after purchasing an additional 51 shares during the last quarter. Synergy Investment Management LLC purchased a new stake in shares of Amgen during the 4th quarter worth $34,000. Finally, Atala Financial Inc purchased a new stake in shares of Amgen during the 4th quarter worth $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Rachna Khosla sold 1,500 shares of the company’s stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president now directly owns 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.76% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $290.33 on Friday. The company has a 50-day simple moving average of $281.57 and a 200-day simple moving average of $285.44. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The stock has a market capitalization of $156.11 billion, a price-to-earnings ratio of 38.45, a PEG ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business had revenue of $8.15 billion during the quarter, compared to analysts’ expectations of $8.05 billion. During the same period in the prior year, the company earned $3.96 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. On average, analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Analyst Ratings Changes

AMGN has been the subject of several recent analyst reports. Morgan Stanley reaffirmed an “equal weight” rating on shares of Amgen in a research report on Friday, May 2nd. Johnson Rice set a $294.00 price objective on shares of Amgen in a research report on Wednesday, March 5th. Royal Bank of Canada decreased their price objective on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. Mizuho lifted their price objective on shares of Amgen from $235.00 to $280.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 7th. Finally, Bank of America lifted their price objective on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.